| Year |
Citation |
Score |
| 2023 |
Juarez D, Buono R, Matulis SM, Gupta VA, Duong MR, Yudiono J, Paul M, Mallya S, Diep G, Hsin P, Lu A, Suh SM, Dong VM, Roberts AW, Leverson JD, ... ... Boise LH, et al. Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL1 inhibitors. Cancer Research Communications. PMID 37956312 DOI: 10.1158/2767-9764.CRC-23-0350 |
0.414 |
|
| 2021 |
Gupta VA, Barwick BG, Matulis SM, Shirasaki R, Jaye DL, Keats J, Oberlton B, Joseph N, Hofmeister C, Heffner LT, Dhodapkar MV, Nooka AK, Lonial S, Mitsiades CS, Kaufman JL, ... Boise LH, et al. Venetoclax sensitivity in multiple myeloma is associated with B cell gene expression. Blood. PMID 33649772 DOI: 10.1182/blood.2020007899 |
0.332 |
|
| 2020 |
Gu Y, Barwick BG, Shanmugam M, Hofmeister CC, Kaufman J, Nooka A, Gupta V, Dhodapkar M, Boise LH, Lonial S. Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood Cancer Journal. 10: 125. PMID 33318477 DOI: 10.1038/s41408-020-00393-0 |
0.328 |
|
| 2020 |
Matulis SM, Boise LH. BCL2 dependency in diffuse large B-cell lymphoma: it's a family affair. Haematologica. 105: 1993-1996. PMID 32739887 DOI: 10.3324/Haematol.2020.253591 |
0.318 |
|
| 2020 |
Li Y, Zhang B, Xiang L, Xia S, Kucuk O, Deng X, Boise LH, Dong JT. TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Theranostics. 10: 7656-7670. PMID 32685011 DOI: 10.7150/Thno.44567 |
0.32 |
|
| 2020 |
Utley A, Chavel C, Lightman S, Holling GA, Cooper J, Peng P, Liu W, Barwick BG, Gavile CM, Maguire O, Murray-Dupuis M, Rozanski C, Jordan MS, Kambayashi T, Olejniczak SH, ... Boise LH, et al. CD28 Regulates Metabolic Fitness for Long-Lived Plasma Cell Survival. Cell Reports. 31: 107815. PMID 32579940 DOI: 10.1016/J.Celrep.2020.107815 |
0.352 |
|
| 2020 |
Bajpai R, Sharma A, Achreja A, Edgar CL, Wei C, Siddiqa AA, Gupta VA, Matulis SM, McBrayer SK, Mittal A, Rupji M, Barwick BG, Lonial S, Nooka AK, Boise LH, et al. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nature Communications. 11: 1228. PMID 32144272 DOI: 10.1038/S41467-020-15051-Z |
0.349 |
|
| 2020 |
Sborov DW, Viola D, Dona AA, Nooka AK, Kaufman JL, Lonial S, Boise L, Dhodapkar MV, Joseph N, Pichiorri F, Hofmeister CC. Oncolytic virus pelareorep plus carfilzomib phase I trial in carfilzomib-refractory patients (NCI 9603): Responses with cytokine storm. Journal of Clinical Oncology. 38: 8535-8535. DOI: 10.1200/Jco.2020.38.15_Suppl.8535 |
0.32 |
|
| 2019 |
Lin YT, Way GP, Barwick BG, Mariano MC, Marcoulis M, Ferguson ID, Driessen C, Boise LH, Greene CS, Wiita AP. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma. Blood Advances. 3: 3214-3227. PMID 31698452 DOI: 10.1182/Bloodadvances.2019000303 |
0.324 |
|
| 2019 |
Boise LH. Myeloma's sound of silencing. Blood. 134: 1116-1117. PMID 31582370 DOI: 10.1182/Blood.2019002742 |
0.337 |
|
| 2019 |
Sharma A, Boise LH, Shanmugam M. Cancer Metabolism and the Evasion of Apoptotic Cell Death. Cancers. 11. PMID 31405035 DOI: 10.3390/Cancers11081144 |
0.428 |
|
| 2019 |
Barwick BG, Gupta VA, Vertino PM, Boise LH. Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Frontiers in Immunology. 10: 1121. PMID 31231360 DOI: 10.3389/Fimmu.2019.01121 |
0.362 |
|
| 2019 |
Boise LH, Shanmugam M. Stromal Support of Metabolic Function through Mitochondrial Transfer in Multiple Myeloma. Cancer Research. 79: 2102-2103. PMID 31043428 DOI: 10.1158/0008-5472.Can-19-0500 |
0.371 |
|
| 2019 |
Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S. Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clinical Lymphoma, Myeloma & Leukemia. PMID 31023594 DOI: 10.1016/J.Clml.2019.02.004 |
0.341 |
|
| 2019 |
Barwick BG, Neri P, Bahlis NJ, Nooka AK, Dhodapkar MV, Jaye DL, Hofmeister CC, Kaufman JL, Gupta VA, Auclair D, Keats JJ, Lonial S, Vertino PM, Boise LH. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nature Communications. 10: 1911. PMID 31015454 DOI: 10.1038/S41467-019-09555-6 |
0.313 |
|
| 2019 |
Bailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton KE, Nooka AK, Neparidze N, Parker TL, Bar N, Kaufman JL, Hofmeister CC, Boise LH, Lonial S, Kemp ML, Dhodapkar KM, et al. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. Jci Insight. 5. PMID 31013254 DOI: 10.1172/Jci.Insight.127807 |
0.315 |
|
| 2019 |
Ponder KG, Boise LH. The prodomain of caspase-3 regulates its own removal and caspase activation. Cell Death Discovery. 5: 56. PMID 30701088 DOI: 10.1038/S41420-019-0142-1 |
0.445 |
|
| 2019 |
Fruman D, Juarez D, Diep G, Nguyen F, Gupta VA, Boise LH. Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845 Blood. 134: 4413-4413. DOI: 10.1182/Blood-2019-131218 |
0.478 |
|
| 2019 |
De Matos Simoes R, Shirasaki R, Downey-Kopyscinski SL, Matthews G, Yiguo H, Sheffer M, Dhimolea E, Dashevsky O, Gandolfi S, Dempster J, Meyers RM, Bryan J, McFarland JM, Brueggenthies J, Tang H, ... ... Boise LH, et al. Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma Blood. 134: 4407-4407. DOI: 10.1182/Blood-2019-130901 |
0.359 |
|
| 2019 |
Shirasaki R, Gandolfi S, De Matos Simoes R, Matthews GM, Buckley D, Raja J, Sievers QL, Dashevsky O, Poarch H, Tang H, Bariteau M, Sheffer M, Downey-Kopyscinski SL, Hengeveld P, Glassner B, ... ... Boise LH, et al. Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins Blood. 134: 318-318. DOI: 10.1182/Blood-2019-130549 |
0.336 |
|
| 2019 |
Gu Y, Barwick BG, Shanmugam M, Hofmeister CC, Kaufman JL, Nooka AK, Gupta VA, Dhodapkar MV, Boise LH, Lonial S. The Role of Proteasome Activator PA28α in Multiple Myeloma Blood. 134: 5499-5499. DOI: 10.1182/Blood-2019-128216 |
0.394 |
|
| 2019 |
Neri P, Maity R, Alberge J, Sinha S, Donovan J, Kong M, Hasan F, Jaffer A, Boise LH, Bahlis N. Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients Blood. 134: 572-572. DOI: 10.1182/Blood-2019-127593 |
0.459 |
|
| 2019 |
Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, Boise LH, Alzate S, Macartney T, Pesko J, Salem AH, Ross JA, Hong W, Maciag PC, Pauff JM, et al. Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma Blood. 134: 926-926. DOI: 10.1182/Blood-2019-125871 |
0.305 |
|
| 2019 |
Bajpai R, Achreja A, Wei C, Siddiqa A, Matulis SM, Gupta V, McBrayer SK, Mittal A, Rupji M, Chen H, Kowalski J, Lonial S, Nooka AK, Boise LH, Nagrath D, et al. Abstract 2715: Deciphering a metabolic basis for single-agent venetoclax efficacy in t(11;14) multiple myeloma Cancer Research. 79: 2715-2715. DOI: 10.1158/1538-7445.Am2019-2715 |
0.432 |
|
| 2019 |
Shirasaki R, de Matos Simoes R, Gandolfi S, Matthews G, Buckley D, Raja J, Sievers Q, Bruggenthies J, Dashevsky O, Poarch H, Tang H, Bariteau M, Sheffer M, Hu Y, Downey-Kopyscinski S, ... ... Boise L, et al. Molecular markers of myeloma cell sensitivity vs. resistance to heterobifunctional degraders of oncoproteins: therapeutic implications. Clinical Lymphoma Myeloma and Leukemia. 19: e134. DOI: 10.1016/J.Clml.2019.09.222 |
0.32 |
|
| 2019 |
Shirasaki R, de Matos Simoes R, Downey-Kopyscinski S, Matthews G, Hu Y, Sheffer M, Dhimolea E, Dashevsky O, Gandolfi S, Hengeveld P, Dempster J, Meyers R, Bryan J, Dharia N, McFarland J, ... ... Boise L, et al. CRISPR studies identify genes preferentially essential for myeloma cells vs. other neoplasias: implications for future therapies selective against MM Clinical Lymphoma Myeloma and Leukemia. 19: e48-e49. DOI: 10.1016/J.Clml.2019.09.073 |
0.302 |
|
| 2018 |
Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, Cidado J, Embrey KJ, Gangl E, Gibbons FD, Gregory GP, Hargreaves D, Hendricks JA, Johannes JW, Johnstone RW, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature Communications. 9: 5341. PMID 30559424 DOI: 10.1038/S41467-018-07551-W |
0.464 |
|
| 2018 |
Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, Boise LH, Dhodapkar MV, Gleason C, Nooka AK, Lonial S. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer. PMID 30332496 DOI: 10.1002/Cncr.31718 |
0.323 |
|
| 2018 |
Jin L, Chun J, Pan C, Li D, Lin R, Alesi GN, Wang X, Kang HB, Song L, Wang D, Zhang G, Fan J, Boggon TJ, Zhou L, Kowalski J, ... ... Boise LH, et al. MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell. PMID 30033091 DOI: 10.1016/J.Ccell.2018.06.012 |
0.36 |
|
| 2018 |
Conage-Pough JE, Boise LH. Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming. The Febs Journal. PMID 29775995 DOI: 10.1111/Febs.14505 |
0.325 |
|
| 2018 |
Shirasaki R, Gandolfi S, De Matos Simoes R, Matthews G, Buckley D, Dashevsky O, Downey-Kopyscinski SL, Tang H, Sheffer M, Dhimolea E, Glassner B, Bariteau M, Sorrell J, Bruggenthies JB, Sievers Q, ... ... Boise LH, et al. CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias Blood. 132: 1367-1367. DOI: 10.1182/Blood-2018-99-116232 |
0.35 |
|
| 2018 |
Moser-Katz T, Gavile CM, Barwick BG, Lonial S, Boise LH. A Role for Syntenin-1 in Multiple Myeloma Cell Survival Blood. 132: 1008-1008. DOI: 10.1182/Blood-2018-99-113594 |
0.396 |
|
| 2018 |
Barwick BG, Neri P, Bahlis N, Nooka AK, Kaufman JL, Gupta VA, Auclair D, Keats JJ, Lonial S, Vertino PM, Boise LH. Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy Blood. 132: 405-405. DOI: 10.1182/Blood-2018-99-113585 |
0.326 |
|
| 2018 |
Matulis SM, Gupta VA, Brown I, Keats JJ, Secrist P, Cidado J, Tron AE, Neri P, Bahlis N, Kaufman JL, Heffner L, Lonial S, Nooka AK, Boise LH. Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma Blood. 132: 952-952. DOI: 10.1182/Blood-2018-99-113504 |
0.448 |
|
| 2018 |
Chen B, Pamela W, Auclair D, Keats JJ, Secrist P, Cidado J, Tron AE, Dunham CM, Lonial S, Opferman J, Matulis SM, Boise LH. Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function Blood. 132: 951-951. DOI: 10.1182/Blood-2018-99-113444 |
0.357 |
|
| 2018 |
Moser-Katz T, Gavile CM, Barwick BG, Lonial S, Boise LH. Abstract 319: Syntenin regulates multiple myeloma cell survival Cancer Research. 78: 319-319. DOI: 10.1158/1538-7445.Am2018-319 |
0.389 |
|
| 2017 |
Gavile CM, Barwick BG, Newman S, Neri P, Nooka AK, Lonial S, Lee KP, Boise LH. CD86 regulates myeloma cell survival. Blood Advances. 1: 2307-2319. PMID 29296880 DOI: 10.1182/Bloodadvances.2017011601 |
0.367 |
|
| 2017 |
Shah SP, Nooka AK, Lonial S, Boise LH. TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma. Blood Advances. 1: 1848-1853. PMID 29296831 DOI: 10.1182/Bloodadvances.2017006122 |
0.348 |
|
| 2017 |
Konen J, Summerbell E, Dwivedi B, Galior K, Hou Y, Rusnak L, Chen A, Saltz J, Zhou W, Boise LH, Vertino P, Cooper L, Salaita K, Kowalski J, Marcus AI. Image-guided genomics of phenotypically heterogeneous populations reveals vascular signalling during symbiotic collective cancer invasion. Nature Communications. 8: 15078. PMID 28497793 DOI: 10.1038/Ncomms15078 |
0.335 |
|
| 2017 |
Zhao L, Fan J, Xia S, Pan Y, Liu S, Qian G, Qian Z, Kang HB, Arbiser JL, Pollack BP, Kudchadkar R, Lawson DH, Rossi M, Abdel-Wahab O, Merghoub T, ... ... Boise LH, et al. HMG-CoA synthase 1 is a synthetic lethal partner of BRAF(V600E) in human cancers. The Journal of Biological Chemistry. PMID 28468827 DOI: 10.1074/Jbc.M117.788778 |
0.353 |
|
| 2017 |
Guo X, Koff JL, Moffitt AB, Cinar M, Ramachandiran S, Chen Z, Switchenko JM, Mosunjac M, Neill SG, Mann KP, Bagirov M, Du Y, Natkunam Y, Khoury HJ, Rossi MR, ... ... Boise LH, et al. Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. Oncogene. PMID 28368397 DOI: 10.1038/Onc.2017.90 |
0.32 |
|
| 2017 |
Gupta VA, Matulis SM, Conage-Pough JE, Nooka AK, Kaufman JL, Lonial S, Boise LH. Bone marrow microenvironment derived signals induce Mcl-1 dependence in multiple myeloma. Blood. PMID 28151428 DOI: 10.1182/Blood-2016-10-745059 |
0.476 |
|
| 2017 |
Boise LH. Protein Homeostasis: A Key Target in Myeloma Blood. 130. DOI: 10.1182/Blood.V130.Suppl_1.Sci-8.Sci-8 |
0.441 |
|
| 2017 |
Kaufman JL, Gasparetto CJ, Mikhael J, Moreau P, Touzeau C, Vij R, Facon T, Pegourie B, Benboubker L, Boise LH, Alzate S, Dunbar M, Jia J, Freise KJ, Verdugo M, et al. Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma Blood. 130: 3131-3131. DOI: 10.1182/Blood.V130.Suppl_1.3131.3131 |
0.347 |
|
| 2017 |
Matulis S, Gupta VA, Tang Z, Shah S, Adewuya T, Nooka A, Kaufman JL, Lonial S, Boise LH. Predicting Venetoclax Sensitivity in Multiple Myeloma Using Biologic Activity Assays Blood. 130: 3056-3056. DOI: 10.1182/Blood.V130.Suppl_1.3056.3056 |
0.349 |
|
| 2017 |
Barwick B, Gupta VA, Auclair D, Keats JJ, Lonial S, Vertino PM, Boise LH. High-Risk Myeloma Is Demarcated By Immunoglobulin Lambda Light Chain Translocations Blood. 130: 1780-1780. DOI: 10.1182/Blood.V130.Suppl_1.1780.1780 |
0.339 |
|
| 2016 |
Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, Belmar J, Shaw S, Tarr JC, Veerasamy N, Matulis SM, Koss B, Fischer MA, Arnold AL, Camper DV, ... ... Boise LH, et al. Discovery and Biological Characterization of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors. Febs Letters. PMID 27878989 DOI: 10.1002/1873-3468.12497 |
0.441 |
|
| 2016 |
Shah SP, Nooka AK, Jaye DL, Bahlis NJ, Lonial S, Boise LH. Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. Oncotarget. PMID 27487129 DOI: 10.18632/Oncotarget.10847 |
0.359 |
|
| 2016 |
Ponder KG, Matulis SM, Hitosugi S, Gupta VA, Sharp C, Burrows F, Nooka AK, Kaufman JL, Lonial S, Boise LH. Dual Inhibition of Mcl-1 by the Combination of Carfilzomib and TG02 In Multiple Myeloma. Cancer Biology & Therapy. 0. PMID 27246906 DOI: 10.1182/Blood.V122.21.3171.3171 |
0.439 |
|
| 2016 |
Deng J, Park D, Wang M, Nooka A, Deng Q, Matulis S, Kaufman J, Lonial S, Boise LH, Galipeau J, Deng X. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget. PMID 27049723 DOI: 10.18632/Oncotarget.8513 |
0.51 |
|
| 2016 |
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, ... ... Boise LH, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12: 1-222. PMID 26799652 DOI: 10.1080/15548627.2015.1100356 |
0.365 |
|
| 2016 |
Gupta VA, Newman S, Bahlis NJ, Keats JJ, Matulis S, Rossi MR, Auclair D, Network MC, Nooka AK, Kaufman JL, Lonial S, Boise LH. B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma Blood. 128: 2108-2108. DOI: 10.1182/Blood.V128.22.2108.2108 |
0.406 |
|
| 2015 |
Matulis SM, Gupta VA, Nooka AK, Von Hollen H, Kaufman JL, Lonial S, Boise LH. Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax. Leukemia. PMID 26707935 DOI: 10.1038/Leu.2015.350 |
0.462 |
|
| 2015 |
Bajpai R, Matulis SM, Wei C, Nooka AK, Von Hollen HE, Lonial S, Boise LH, Shanmugam M. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene. PMID 26640142 DOI: 10.1038/Onc.2015.464 |
0.464 |
|
| 2015 |
Boise LH. DUB-ling down on B-cell malignancies. Blood. 125: 3522-3. PMID 26045592 DOI: 10.1182/Blood-2015-04-638262 |
0.361 |
|
| 2015 |
Shah SP, Lonial S, Boise LH. When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat Shock Response. Molecular Cancer Research : McR. PMID 26013169 DOI: 10.1158/1541-7786.Mcr-15-0135 |
0.349 |
|
| 2015 |
Gaudette BT, Dwivedi B, Chitta KS, Poulain S, Powell D, Vertino P, Leleu X, Lonial S, Chanan-Khan AA, Kowalski J, Boise LH. Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia. Oncogene. PMID 25893290 DOI: 10.1038/Onc.2015.103 |
0.472 |
|
| 2015 |
Rozanski CH, Utley A, Carlson LM, Farren MR, Murray M, Russell LM, Nair JR, Yang Z, Brady W, Garrett-Sinha LA, Schoenberger SP, Green JM, Boise LH, Lee KP. CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif. Journal of Immunology (Baltimore, Md. : 1950). 194: 4717-28. PMID 25833397 DOI: 10.4049/Jimmunol.1402260 |
0.304 |
|
| 2015 |
Mishima Y, Santo L, Eda H, Cirstea D, Nemani N, Yee AJ, O'Donnell E, Selig MK, Quayle SN, Arastu-Kapur S, Kirk C, Boise LH, Jones SS, Raje N. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. British Journal of Haematology. 169: 423-34. PMID 25709080 DOI: 10.1111/Bjh.13315 |
0.454 |
|
| 2015 |
Ramachandiran S, Adon A, Guo X, Wang Y, Wang H, Chen Z, Kowalski J, Sunay UR, Young AN, Brown T, Mar JC, Du Y, Fu H, Mann KP, Natkunam Y, ... Boise LH, et al. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway. International Journal of Cancer. Journal International Du Cancer. 136: 2341-51. PMID 25359525 DOI: 10.1002/Ijc.29301 |
0.345 |
|
| 2015 |
Deng J, Park D, Wang M, Deng Q, Matulis S, Boise LH, Deng X. Small Molecule Bda-366 As a Bcl2-BH4 Antagonist for Multiple Myeloma Therapy Blood. 126: 2049-2049. DOI: 10.1182/Blood.V126.23.2049.2049 |
0.472 |
|
| 2015 |
Bajpai R, Matulis SM, Wei C, Nooka AK, Boise LH, Shanmugam M. Abstract 972: Targeting glucose and glutamine regulated BCL2 family members for multiple myeloma therapy Cancer Research. 75: 972-972. DOI: 10.1158/1538-7445.Am2015-972 |
0.453 |
|
| 2014 |
Boise LH. To Gli or not to Gli. Blood. 124: 2008-9. PMID 25258136 DOI: 10.1182/Blood-2014-08-592311 |
0.323 |
|
| 2014 |
Boise LH, Kaufman JL, Bahlis NJ, Lonial S, Lee KP. The Tao of myeloma. Blood. 124: 1873-9. PMID 25097176 DOI: 10.1182/Blood-2014-05-578732 |
0.34 |
|
| 2014 |
Gaudette BT, Iwakoshi NN, Boise LH. Bcl-xL protein protects from C/EBP homologous protein (CHOP)-dependent apoptosis during plasma cell differentiation. The Journal of Biological Chemistry. 289: 23629-40. PMID 25023286 DOI: 10.1074/Jbc.M114.569376 |
0.512 |
|
| 2014 |
Wijesinghe DS, Brentnall M, Mietla JA, Hoeferlin LA, Diegelmann RF, Boise LH, Chalfant CE. Ceramide kinase is required for a normal eicosanoid response and the subsequent orderly migration of fibroblasts. Journal of Lipid Research. 55: 1298-1309. PMID 24823941 DOI: 10.1194/Jlr.M048207 |
0.733 |
|
| 2014 |
Murray ME, Gavile CM, Nair JR, Koorella C, Carlson LM, Buac D, Utley A, Chesi M, Bergsagel PL, Boise LH, Lee KP. CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood. 123: 3770-9. PMID 24782505 DOI: 10.1182/Blood-2013-10-530964 |
0.365 |
|
| 2014 |
Gu Y, Kaufman JL, Bernal L, Torre C, Matulis SM, Harvey RD, Chen J, Sun SY, Boise LH, Lonial S. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood. 123: 3269-76. PMID 24713927 DOI: 10.1182/Blood-2013-08-521914 |
0.472 |
|
| 2014 |
Brentnall M, Weir DB, Rongvaux A, Marcus AI, Boise LH. Procaspase-3 regulates fibronectin secretion and influences adhesion, migration and survival independently of catalytic function. Journal of Cell Science. 127: 2217-26. PMID 24610949 DOI: 10.1242/Jcs.135137 |
0.811 |
|
| 2014 |
Gavile CM, Nooka AK, Lonial S, Lee KP, Boise LH. Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells Blood. 124: 4726-4726. DOI: 10.1182/Blood.V124.21.4726.4726 |
0.405 |
|
| 2014 |
Oberlton B, Matulis S, Boise LH. Induction of Bim-Dependent and -Independent Apoptosis in Multiple Myeloma Blood. 124: 4716-4716. DOI: 10.1182/Blood.V124.21.4716.4716 |
0.505 |
|
| 2014 |
Matulis S, Nooka AK, Von Hollen H, Kaufman JL, Lonial S, Boise LH. Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma Blood. 124: 3447-3447. DOI: 10.1182/Blood.V124.21.3447.3447 |
0.47 |
|
| 2014 |
Ramachandiran S, Koff JL, Garderet L, Saxe D, Ikhlef S, Kelkar N, Kaplan L, El-Cheikh J, Switchenko JM, Sunay S, Khoury HJ, Kaufman JL, Lonial S, Boise LH, Kowalski J, et al. Detection of NFKB2 3’end Loos By Quantitative PCR (QPCR) or Detection of NFKB2 Rearrangements Correlate with Bortezomib Response in Multiple Myeloma Blood. 124: 2138-2138. DOI: 10.1182/Blood.V124.21.2138.2138 |
0.37 |
|
| 2014 |
Gaudette BT, Boise LH. Mir-155 Expression Raises the Apoptotic Threshold in Waldenström Macroglobulinemia By Inhibition of FOXO3a and Bim Blood. 124: 1671-1671. DOI: 10.1182/Blood.V124.21.1671.1671 |
0.42 |
|
| 2014 |
Gupta VA, Matulis SM, Nooka AK, Kaufman JL, Lonial S, Boise LH. Transcriptional and Post-translational Regulation of the Bcl-2 Family by IL-6 Mediates Resistance to ABT-737 in Multiple Myeloma Clinical Lymphoma Myeloma and Leukemia. 14: S148. DOI: 10.1016/J.Clml.2014.06.088 |
0.306 |
|
| 2013 |
Lonial S, Boise LH. The future of drug development and therapy in myeloma. Seminars in Oncology. 40: 652-8. PMID 24135409 DOI: 10.1053/J.Seminoncol.2013.07.004 |
0.315 |
|
| 2013 |
Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. Bmc Cell Biology. 14: 32. PMID 23834359 DOI: 10.1186/1471-2121-14-32 |
0.777 |
|
| 2013 |
Matulis SM, Sharp C, Nooka AK, Kaufman JL, Lonial S, Boise LH. Efficacy Of ABT-199 In Multiple Myeloma Blood. 122: 4453-4453. DOI: 10.1182/Blood.V122.21.4453.4453 |
0.48 |
|
| 2013 |
Egas D, Doho GH, Lonial S, Lee KP, Boise LH. CD28 and CD86 Regulate Integrin Surface Expression In Multiple Myeloma Blood. 122: 4450-4450. DOI: 10.1182/Blood.V122.21.4450.4450 |
0.307 |
|
| 2013 |
Conage-Pough JE, Gupta VA, Matulis SM, Boise LH. Phosphorylation Influences The Binding Of Bim To Anti-Apoptotic Proteins In Multiple Myeloma Blood. 122: 4446-4446. DOI: 10.1182/Blood.V122.21.4446.4446 |
0.433 |
|
| 2013 |
Gaudette BT, Chitta KS, Poulain S, Lee KP, Chanan-Khan A, Ansell SM, Leleu X, Lonial S, Boise LH. Heterogeneous Bcl-2 Family Expression In Waldenström Macroglobulinemia Determines Response To Inducers Of Intrinsic Apoptosis Blood. 122: 4287-4287. DOI: 10.1182/Blood.V122.21.4287.4287 |
0.475 |
|
| 2013 |
Torre C, Gu Y, Boise LH, Lonial S. Combined Carfilzomib and Selective PI3Kδ Inhibition (TGR1202) Results In Enhanced Myeloma Cell Apoptosis Blood. 122: 3224-3224. DOI: 10.1182/Blood.V122.21.3224.3224 |
0.5 |
|
| 2013 |
Shah SP, Gupta VA, Matulis SM, Nooka AK, Lonial S, Boise LH. P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma Blood. 122: 1929-1929. DOI: 10.1182/Blood.V122.21.1929.1929 |
0.418 |
|
| 2013 |
Gupta VA, Matulis SM, Conage-Pough JE, Nooka AK, Kaufman JL, Lonial S, Boise LH. Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma Blood. 122: 1924-1924. DOI: 10.1182/Blood.V122.21.1924.1924 |
0.393 |
|
| 2012 |
Matulis SM, Morales AA, Yehiayan L, Lee KP, Cai Y, Boise LH. Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma. Plos One. 7: e52662. PMID 23285138 DOI: 10.1371/Journal.Pone.0052662 |
0.352 |
|
| 2012 |
Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, ... ... Boise LH, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 8: 445-544. PMID 22966490 DOI: 10.4161/Auto.19496 |
0.335 |
|
| 2012 |
Ramachandiran S, Cain J, Liao A, He Y, Guo X, Boise LH, Fu H, Ratner L, Khoury HJ, Bernal-Mizrachi L. The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. Leukemia Research. 36: 784-90. PMID 22325366 DOI: 10.1016/J.Leukres.2011.12.024 |
0.52 |
|
| 2012 |
Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, Zucker SN, Fink EE, Moparthy KC, Hu Q, Liu S, Boise LH, Lee KP, Nikiforov MA. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood. 119: 1450-8. PMID 22144178 DOI: 10.1182/Blood-2011-04-346676 |
0.491 |
|
| 2012 |
Nair JR, Murray M, Koorella C, Carlson LM, Boise LH, Lee KP. Targeting the Cellular and Molecular Components of CD28 Mediated Survival Signaling in Multiple Myeloma Blood. 120: 722-722. DOI: 10.1182/Blood.V120.21.722.722 |
0.345 |
|
| 2012 |
Vakkalanka S, Viswanadha S, Boise LH, Sportelli P, Miskin H, Lonial S. TGR-1202: A Novel, Targeted PI3Kδ Inhibitor in Multiple Myeloma Blood. 120: 5018-5018. DOI: 10.1182/Blood.V120.21.5018.5018 |
0.443 |
|
| 2012 |
Matulis SM, Liu J, Gupta VA, Conage-Pough JE, Nooka AK, Waller EK, Kaufman JL, Lonial S, Boise LH. Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins Blood. 120: 4024-4024. DOI: 10.1182/Blood.V120.21.4024.4024 |
0.464 |
|
| 2012 |
Kowalski J, Gandhi K, Switchenko J, Liu Y, Kim S, Doho G, Kim SJ, Yang R, Chen L, Qin Z, Newman S, Moreno CS, Vertino PM, Bernal-Mizrachi L, Rossi MR, ... ... Boise LH, et al. Integrative, Multi-Platform, Whole-Genome Analyses Identify Clinically Relevant Common- and Cell-Specific Signatures in Multiple Myeloma Blood. 120: 3974-3974. DOI: 10.1182/Blood.V120.21.3974.3974 |
0.324 |
|
| 2012 |
Gaudette B, Iwakoshi NN, Boise LH. Bcl-xL Protects From UPR-Associated Apoptosis During Plasma Cell Differentiation Blood. 120: 3288-3288. DOI: 10.1182/Blood.V120.21.3288.3288 |
0.471 |
|
| 2012 |
Shah SP, Lonial S, Boise LH. Inhibition of Heat Shock Factor 1 (HSF1) Is More Effective At Sensitizing Myeloma Cells to Bortezomib Than Inhibition of Individual HSF1 Targets. Blood. 120: 2953-2953. DOI: 10.1182/Blood.V120.21.2953.2953 |
0.419 |
|
| 2012 |
Gavile CM, Nair JR, Lee KP, Lonial S, Boise LH. CD28 and CD86 Are Necessary for Myeloma Cell Survival. Blood. 120: 2946-2946. DOI: 10.1182/Blood.V120.21.2946.2946 |
0.35 |
|
| 2012 |
Gu Y, Kaufman JL, Boise LH, Lonial S. The Role of 14-3-3ζ in Regulation of Proteasome Inhibitor Bortezomib Sensitivity in Multiple Myeloma Blood. 120: 1845-1845. DOI: 10.1182/Blood.V120.21.1845.1845 |
0.455 |
|
| 2011 |
Rafei M, Deng J, Boivin MN, Williams P, Matulis SM, Yuan S, Birman E, Forner K, Yuan L, Castellino C, Boise LH, MacDonald TJ, Galipeau J. A MCP1 fusokine with CCR2-specific tumoricidal activity. Molecular Cancer. 10: 121. PMID 21943176 DOI: 10.1186/1476-4598-10-121 |
0.461 |
|
| 2011 |
Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, Duggan P, Tassone P, Mansoor A, Stewart DA, Lonial S, Boise LH, Bahlis NJ. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood. 118: 6368-79. PMID 21917757 DOI: 10.1182/Blood-2011-06-363911 |
0.416 |
|
| 2011 |
Nair JR, Carlson LM, Koorella C, Rozanski CH, Byrne GE, Bergsagel PL, Shaughnessy JP, Boise LH, Chanan-Khan A, Lee KP. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. Journal of Immunology (Baltimore, Md. : 1950). 187: 1243-53. PMID 21715687 DOI: 10.4049/Jimmunol.1100016 |
0.364 |
|
| 2011 |
Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, Kaufman JL, Lee KP, Lonial S, Boise LH. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood. 118: 1329-39. PMID 21659544 DOI: 10.1182/Blood-2011-01-327197 |
0.461 |
|
| 2011 |
Neri P, Ren L, Azab AK, Brentnall M, Gratton K, Klimowicz AC, Lin C, Duggan P, Tassone P, Mansoor A, Stewart DA, Boise LH, Ghobrial IM, Bahlis NJ. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood. 117: 6202-13. PMID 21474670 DOI: 10.1182/Blood-2010-06-292243 |
0.77 |
|
| 2011 |
Nair JR, Murray M, Koorella C, Rozanski CH, Carlson LM, Boise LH, Lee KP. Prosurvival and Immunosuppressive Functions of CD28 in the Myeloma Tumor Microenvironment Blood. 118: 473-473. DOI: 10.1182/Blood.V118.21.473.473 |
0.412 |
|
| 2011 |
Matulis SM, Kaufman JL, Lonial S, Boise LH. Bone Marrow Stromal Cells Enforce MCL-1 Dependence In Multiple Myeloma Through the Secretion of A Soluble Factor, Blood. 118: 3950-3950. DOI: 10.1182/Blood.V118.21.3950.3950 |
0.497 |
|
| 2011 |
Ramachandiran S, Guo X, Garderet L, Ikhlef S, El-cheikh J, Weil MR, Young AN, Bagirov M, Lonial S, Chen Z, Kowalsky J, Du Y, Khoury HJ, Sunay S, Kaufman JL, ... Boise LH, et al. Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma Blood. 118: 2891-2891. DOI: 10.1182/Blood.V118.21.2891.2891 |
0.356 |
|
| 2011 |
Kim S, Moreno CS, Lonial S, Boise LH. ETV1 Is a Survival Gene That Is Expressed in a Subset of Multiple Myeloma Blood. 118: 2884-2884. DOI: 10.1182/Blood.V118.21.2884.2884 |
0.393 |
|
| 2011 |
Rozanski CH, Dodson LF, Arens R, Carlson LM, Russell LM, Nair JR, Chanan-Khan A, Garrett-Sinha LA, Green JM, Schoenberger SP, Boise LH, Lee KP. Sustained Antibody Responses Depend on CD28 Function in Bone Marrow Resident Plasma Cells Blood. 118: 182-182. DOI: 10.1182/Blood.V118.21.182.182 |
0.321 |
|
| 2011 |
Gu Y, Kaufman JL, Boise LH, Lonial S. Validation of the Function of 14-3-3 ζ in Multiple Myeloma (MM) Blood. 118: 1369-1369. DOI: 10.1182/Blood.V118.21.1369.1369 |
0.511 |
|
| 2010 |
David E, Kaufman JL, Flowers CR, Schafer-Hales K, Torre C, Chen J, Marcus AI, Sun SY, Boise LH, Lonial S. Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood. 116: 5285-8. PMID 20844234 DOI: 10.1182/Blood-2010-03-272393 |
0.507 |
|
| 2010 |
Boise LH. Aiming at WM with both barrels blocked. Blood. 115: 4007-8. PMID 20489059 DOI: 10.1182/Blood-2010-02-270231 |
0.33 |
|
| 2010 |
Kurtoglu M, Philips K, Liu H, Boise LH, Lampidis TJ. High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors. Cancer Chemotherapy and Pharmacology. 66: 129-40. PMID 19779717 DOI: 10.1007/S00280-009-1143-1 |
0.43 |
|
| 2010 |
Boise LH, Morales AA, Kurtoglu M, Matulis SM, Markovitz R, Lee KP, Lonial S. Distribution of Bim Determines MCL-1 Dependence or Co-Dependence on BCL-xL/BCL-2 In Multiple Myeloma Blood. 116: 4054-4054. DOI: 10.1182/Blood.V116.21.4054.4054 |
0.49 |
|
| 2010 |
Rozanski CH, Arens R, Carlson L, Nair J, Boise LH, Chanan-Khan AA, Schoenberger SP, Lee KP. Long Term Humoral Immunity Is Dependent on CD28 Expression In Plasma Cells Blood. 116: 1737-1737. DOI: 10.1182/Blood.V116.21.1737.1737 |
0.317 |
|
| 2010 |
Nair J, Carlson L, Rozanski CH, Koorella C, Murray M, Shaughnessy J, Bergsagel P, Boise LH, Chanan-Khan AA, Lee KP. Targeting the CD28-B7 Pro-Survival Pathway In Multiple Myeloma Blood. 116: 132-132. DOI: 10.1182/Blood.V116.21.132.132 |
0.351 |
|
| 2010 |
Gu Y, Kaufman J, Boise LH, Lonial S. Abstract 1635: Combination of the HDAC inhibitor romidepsin with the MEK inhibitor U0126 results in synergistic plasma cell apoptosis Cancer Research. 70: 1635-1635. DOI: 10.1158/1538-7445.Am10-1635 |
0.479 |
|
| 2009 |
Matulis SM, Morales AA, Yehiayan L, Croutch C, Gutman D, Cai Y, Lee KP, Boise LH. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Molecular Cancer Therapeutics. 8: 1197-206. PMID 19417148 DOI: 10.1158/1535-7163.Mct-08-1072 |
0.46 |
|
| 2009 |
Morales AA, Gutman D, Cejas PJ, Lee KP, Boise LH. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. The Journal of Biological Chemistry. 284: 12886-95. PMID 19279006 DOI: 10.1074/Jbc.M806546200 |
0.46 |
|
| 2009 |
Morales AA, Kurtoglu M, Siefker D, Matulis SM, Gutman DM, Boise LH. Displacement of Bim From Anti-Apoptotic Proteins Is the Primary Factor for Determining ABT-737 Activity in Multiple Myeloma Cell Lines. Blood. 114: 2851-2851. DOI: 10.1182/Blood.V114.22.2851.2851 |
0.474 |
|
| 2009 |
Deshpande DS, Lechowicz MJ, Sinha R, Kaufman JL, Boise LH, Lonial S, Flowers CR. The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines. Blood. 114: 1689-1689. DOI: 10.1182/Blood.V114.22.1689.1689 |
0.505 |
|
| 2008 |
Morales AA, Gutman D, Lee KP, Boise LH. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood. 111: 5152-62. PMID 18354037 DOI: 10.1182/Blood-2007-10-116889 |
0.508 |
|
| 2008 |
Morales AA, Siefker D, Matulis SM, Gutman DM, Boise LH. Bak Binding to Bcl-xL and Not to Mcl-1 Is Associated with ABT-737 Sensitivity in Multiple Myeloma Cell Lines Blood. 112: 3675-3675. DOI: 10.1182/Blood.V112.11.3675.3675 |
0.494 |
|
| 2007 |
Bahlis NJ, King AM, Kolonias D, Carlson LM, Liu HY, Hussein MA, Terebelo HR, Byrne GE, Levine BL, Boise LH, Lee KP. CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood. 109: 5002-10. PMID 17311991 DOI: 10.1182/Blood-2006-03-012542 |
0.365 |
|
| 2007 |
Vempati UD, Diaz F, Barrientos A, Narisawa S, Mian AM, Millán JL, Boise LH, Moraes CT. Role of cytochrome C in apoptosis: increased sensitivity to tumor necrosis factor alpha is associated with respiratory defects but not with lack of cytochrome C release. Molecular and Cellular Biology. 27: 1771-83. PMID 17210651 DOI: 10.1128/Mcb.00287-06 |
0.436 |
|
| 2006 |
Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 107: 4907-16. PMID 16507771 DOI: 10.1182/Blood-2005-08-3531 |
0.77 |
|
| 2006 |
Bartimole TM, Vrana JA, Freemerman AJ, Jarvis WD, Reed JC, Boise LH, Grant S. Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis. Cell Death and Differentiation. 4: 294-303. PMID 16465244 DOI: 10.1038/Sj.Cdd.4400242 |
0.493 |
|
| 2006 |
Boise LH, Morales AA, Croutch CR, Gutman D, Gale RP, Lee KP. S-Dimethylarsinoglutathione (SGLU/ZIO101) Is a Novel Active Organic Arsenical That Displays a Unique Gene Expression Profile in Myeloma Cells. Blood. 108: 5043-5043. DOI: 10.1182/Blood.V108.11.5043.5043 |
0.438 |
|
| 2006 |
Morales AA, Gutman D, Cejas PJ, Lee KP, Boise LH. Arsenic Trioxide Induces Up-Regulation of BMF and NOXA and Overcomes an Anti-Oxidative Response To Induce Apoptosis in Myeloma Cells. Blood. 108: 3419-3419. DOI: 10.1182/Blood.V108.11.3419.3419 |
0.506 |
|
| 2006 |
Berenson JR, Boccia RVV, Hussein MA, Belch A, Boise L, Schwartz B, Gale RP, Kornblau SM. Phase-1 Study of ZIO-101: A New Organic Arsenic Active in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM). Blood. 108: 1966-1966. DOI: 10.1182/Blood.V108.11.1966.1966 |
0.318 |
|
| 2005 |
Nawrocki ST, Carew JS, Dunner K, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, McConkey DJ. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Research. 65: 11510-9. PMID 16357160 DOI: 10.1158/0008-5472.Can-05-2394 |
0.439 |
|
| 2005 |
Cejas PJ, Carlson LM, Kolonias D, Zhang J, Lindner I, Billadeau DD, Boise LH, Lee KP. Regulation of RelB expression during the initiation of dendritic cell differentiation. Molecular and Cellular Biology. 25: 7900-16. PMID 16107733 DOI: 10.1128/Mcb.25.17.7900-7916.2005 |
0.344 |
|
| 2005 |
Bahlis NJ, Miao Y, Koc ON, Lee K, Boise LH, Gerson SL. N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. Leukemia & Lymphoma. 46: 899-908. PMID 16019536 DOI: 10.1080/10428190500080595 |
0.469 |
|
| 2005 |
Cepero E, King AM, Coffey LM, Perez RG, Boise LH. Caspase-9 and effector caspases have sequential and distinct effects on mitochondria. Oncogene. 24: 6354-66. PMID 16007191 DOI: 10.1038/Sj.Onc.1208793 |
0.812 |
|
| 2005 |
Obeng EA, Boise LH. Caspase-12 and caspase-4 are not required for caspase-dependent endoplasmic reticulum stress-induced apoptosis. The Journal of Biological Chemistry. 280: 29578-87. PMID 15975932 DOI: 10.1074/Jbc.M502685200 |
0.786 |
|
| 2005 |
Cejas PJ, Carlson LM, Zhang J, Padmanabhan S, Kolonias D, Lindner I, Haley S, Boise LH, Lee KP. Protein kinase C betaII plays an essential role in dendritic cell differentiation and autoregulates its own expression. The Journal of Biological Chemistry. 280: 28412-23. PMID 15917249 DOI: 10.1074/Jbc.M500345200 |
0.326 |
|
| 2005 |
Morales AA, Gutman D, Cejas PJ, Lee KP, Boise LH. Gene Profile during Arsenic Trioxide-Induced Apoptosis in Multiple Myeloma: Strong Anti-Oxidantive Response and Pro-Apoptotic Imbalance. Blood. 106: 5175-5175. DOI: 10.1182/Blood.V106.11.5175.5175 |
0.508 |
|
| 2005 |
Boise LH, Morales AA, Gutman D, Lee KP. In Vitro Activity of a Novel Organic Arsenical (S-Dimethylarsino-Glutathione, ZIO-101) Against Multiple Myeloma. Blood. 106: 5163-5163. DOI: 10.1182/Blood.V106.11.5163.5163 |
0.475 |
|
| 2005 |
Gutman D, Morales A, McCafferty JM, Volz E, Eguizabal T, Lee KP, Boise LH. Glutathione and Glutathione Utilizing Enzymes Are Key Determinants in the Sensitivity of Myeloma Cells to Arsenic Trioxide as Well as Its Mechanism of Action. Blood. 106: 5143-5143. DOI: 10.1182/Blood.V106.11.5143.5143 |
0.496 |
|
| 2004 |
Wilkinson JC, Cepero E, Boise LH, Duckett CS. Upstream regulatory role for XIAP in receptor-mediated apoptosis Molecular and Cellular Biology. 24: 7003-7014. PMID 15282301 DOI: 10.1128/Mcb.24.16.7003-7014.2004 |
0.831 |
|
| 2004 |
Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG. R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Molecular Cancer Therapeutics. 3: 179-86. PMID 14985458 |
0.797 |
|
| 2003 |
Beaupre DM, McCafferty-Grad J, Bahlis NJ, Boise LH, Lichtenheld MG. Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells. Leukemia & Lymphoma. 44: 2123-34. PMID 14959858 DOI: 10.1080/1042819031000116652 |
0.522 |
|
| 2003 |
McCafferty-Grad J, Bahlis NJ, Krett N, Aguilar TM, Reis I, Lee KP, Boise LH. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Molecular Cancer Therapeutics. 2: 1155-64. PMID 14617789 |
0.44 |
|
| 2003 |
Ghosh SK, Wood C, Boise LH, Mian AM, Deyev VV, Feuer G, Toomey NL, Shank NC, Cabral L, Barber GN, Harrington WJ. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood. 101: 2321-7. PMID 12406882 DOI: 10.1182/Blood-2002-08-2525 |
0.42 |
|
| 2001 |
Grad JM, Bahlis NJ, Boise LH. Ascorbic Acid Augments Arsenic-Mediated Cell Death in Multiple Myeloma (MM) Cells. Thescientificworldjournal. 1: 110. PMID 30147593 DOI: 10.1100/Tsw.2001.123 |
0.46 |
|
| 2001 |
Johnson BW, Cepero E, Boise LH. Conversion from a Type I to a Type II Death Receptor-Mediated Pathway through A Partial Inhibition of Caspase-8. Thescientificworldjournal. 1: 98. PMID 30147577 DOI: 10.1100/Tsw.2001.209 |
0.829 |
|
| 2001 |
Cepero E, Johnson BW, Boise LH. Mitochondrial Depolarization During TNF-induced Apoptosis is Caspase-dependent and Independent of Bcl-x L and the Permeability Transition Pore. Thescientificworldjournal. 1: 60. PMID 30147531 DOI: 10.1100/Tsw.2001.180 |
0.831 |
|
| 2001 |
Toomey NL, Deyev VV, Wood C, Boise LH, Scott D, Liu LH, Cabral L, Podack ER, Barber GN, Harrington WJ. Induction of a TRAIL mediated suicide program by interferon alpha in primary effusion lymphoma Oncogene. 20: 7029-7040. PMID 11704827 DOI: 10.1038/Sj.Onc.1204895 |
0.418 |
|
| 2001 |
Grad JM, Cepero E, Boise LH. Mitochondria as targets for established and novel anti-cancer agents. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 4: 85-91. PMID 11512525 DOI: 10.1054/Drup.2001.0192 |
0.784 |
|
| 2001 |
Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood. 98: 805-13. PMID 11468182 DOI: 10.1182/Blood.V98.3.805 |
0.431 |
|
| 2001 |
Cepero E, Johnson BW, Boise LH. Cloning and analysis of Bcl-2 family genes Methods in Cell Biology. 29-47. PMID 11396008 DOI: 10.1016/S0091-679X(01)66003-5 |
0.809 |
|
| 2001 |
Boise LH, Collins CM. Salmonella-induced cell death: Apoptosis, necrosis or programmed cell death? Trends in Microbiology. 9: 64-67. PMID 11173244 DOI: 10.1016/S0966-842X(00)01937-5 |
0.49 |
|
| 2001 |
Grad JM, Zeng XR, Boise LH. Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Current Opinion in Oncology. 12: 543-9. PMID 11085453 DOI: 10.1097/00001622-200011000-00006 |
0.459 |
|
| 2000 |
Jost M, Huggett TM, Kari C, Boise LH, Rodeck U. Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. The Journal of Biological Chemistry. 276: 6320-6. PMID 11098053 DOI: 10.1074/Jbc.M008210200 |
0.365 |
|
| 2000 |
Muta H, Boise LH, Fang L, Podack ER. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. Journal of Immunology (Baltimore, Md. : 1950). 165: 5105-11. PMID 11046041 DOI: 10.4049/Jimmunol.165.9.5105 |
0.385 |
|
| 2000 |
Tang L, Boise LH, Dent P, Grant S. Potentiation of 1-β-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing Bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01) Biochemical Pharmacology. 60: 1445-1456. PMID 11020446 DOI: 10.1016/S0006-2952(00)00463-9 |
0.507 |
|
| 2000 |
Johnson BW, Cepero E, Boise LH. Bcl-x(L) inhibits cytochrome c release but not mitochondria depolarization during the activation of multiple death pathways by tumor necrosis factor-α Journal of Biological Chemistry. 275: 31546-31553. PMID 10913120 DOI: 10.1074/Jbc.M001363200 |
0.82 |
|
| 1999 |
Wang S, Wang Z, Boise LH, Dent P, Grant S. Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia. 13: 1564-73. PMID 10516758 DOI: 10.1038/Sj.Leu.2401532 |
0.527 |
|
| 1999 |
Johnson BW, Boise LH. Bcl-2 and caspase inhibition cooperate to inhibit tumor necrosis factor- α-induced cell death in a bcl-2 cleavage-independent fashion Journal of Biological Chemistry. 274: 18552-18558. PMID 10373464 DOI: 10.1074/Jbc.274.26.18552 |
0.543 |
|
| 1999 |
Wang S, Wang Z, Boise L, Dent P, Grant S. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochemical and Biophysical Research Communications. 259: 67-72. PMID 10334917 DOI: 10.1006/Bbrc.1999.0669 |
0.495 |
|
| 1998 |
Haughn L, Leung B, Boise L, Veillette A, Thompson C, Julius M. Interleukin 2-mediated uncoupling of T cell receptor alpha/beta from CD3 signaling. The Journal of Experimental Medicine. 188: 1575-86. PMID 9802969 DOI: 10.1084/Jem.188.9.1575 |
0.317 |
|
| 1997 |
Blair PJ, Boise LH, Perfetto SP, Levine BL, McCrary G, Wagner KF, St Louis DC, Thompson CB, Siegel JN, June CH. Impaired induction of the apoptosis-protective protein Bcl-xL in activated PBMC from asymptomatic HIV-infected individuals. Journal of Clinical Immunology. 17: 234-46. PMID 9168404 DOI: 10.1023/A:1027310612323 |
0.398 |
|
| 1997 |
Boise LH, Thompson CB. Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation Proceedings of the National Academy of Sciences of the United States of America. 94: 3759-3764. PMID 9108051 DOI: 10.1073/Pnas.94.8.3759 |
0.509 |
|
| 1997 |
Noel PJ, Boise LH, Thompson CB. Regulation of T cell activation by CD28 and CTLA4. Advances in Experimental Medicine and Biology. 406: 209-17. PMID 8910687 DOI: 10.1007/978-1-4899-0274-0_22 |
0.486 |
|
| 1997 |
Minn AJ, Boise LH, Thompson CB. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes & Development. 10: 2621-31. PMID 8895663 DOI: 10.1101/Gad.10.20.2621 |
0.453 |
|
| 1996 |
Eves EM, Boise LH, Thompson CB, Wagner AJ, Hay N, Rosner MR. Apoptosis induced by differentiation or serum deprivation in an immortalized central nervous system neuronal cell line Journal of Neurochemistry. 67: 1908-1920. PMID 8863495 DOI: 10.1046/J.1471-4159.1996.67051908.X |
0.485 |
|
| 1996 |
Boise LH, Thompson CB. Hierarchical control of lymphocyte survival Science. 274: 67-68. PMID 8848725 DOI: 10.1126/Science.274.5284.67 |
0.305 |
|
| 1996 |
Boise LH, McShan CL, Thompson CB. Introduction of the cell survival gene bcl-xL improves the viability of CTLL-2 cells without affecting their IL-2 proliferative response. Implications for the development of bioassays. Journal of Immunological Methods. 191: 143-8. PMID 8666833 DOI: 10.1016/0022-1759(96)00011-7 |
0.363 |
|
| 1996 |
Minn AJ, Boise LH, Thompson CB. Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). The Journal of Biological Chemistry. 271: 6306-12. PMID 8626425 DOI: 10.1074/Jbc.271.11.6306 |
0.37 |
|
| 1996 |
Cheng EH, Levine B, Boise LH, Thompson CB, Hardwick JM. Bax-independent inhibition of apoptosis by Bcl-XL. Nature. 379: 554-6. PMID 8596636 DOI: 10.1038/379554A0 |
0.504 |
|
| 1996 |
Boise LH, Noel PJ, Thompson CB. CD28 and apoptosis. Current Opinion in Immunology. 7: 620-5. PMID 8573303 DOI: 10.1016/0952-7915(95)80067-0 |
0.393 |
|
| 1995 |
Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 80: 285-91. PMID 7834748 DOI: 10.1016/0092-8674(95)90411-5 |
0.51 |
|
| 1995 |
González-García M, García I, Ding L, O'Shea S, Boise LH, Thompson CB, Núñez G. bcl-x is expressed in embryonic and postnatal neural tissues and functions to prevent neuronal cell death. Proceedings of the National Academy of Sciences of the United States of America. 92: 4304-8. PMID 7753802 DOI: 10.1073/Pnas.92.10.4304 |
0.354 |
|
| 1995 |
Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. Bcl-XL and Bcl-2 repress a common pathway of cell death. The Journal of Experimental Medicine. 182: 821-8. PMID 7650488 DOI: 10.1084/Jem.182.3.821 |
0.509 |
|
| 1995 |
Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, Korsmeyer SJ. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proceedings of the National Academy of Sciences of the United States of America. 92: 7834-8. PMID 7644501 DOI: 10.1073/Pnas.92.17.7834 |
0.491 |
|
| 1995 |
Boise LH, Gottschalk AR, Quintans J, Thompson CB. Bcl-2 and Bcl-2-related proteins in apoptosis regulation Current Topics in Microbiology and Immunology. 200: 107-121. PMID 7634826 DOI: 10.1007/978-3-642-79437-7_8 |
0.468 |
|
| 1995 |
Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 3: 87-98. PMID 7621080 DOI: 10.1016/1074-7613(95)90161-2 |
0.39 |
|
| 1995 |
Choi MSK, Boise LH, Gottschalk AR, Quintans J, Thompson CB, Klaus GGB. The role of bcl-xL in CD40-mediated rescue from anti-μ-induced apoptosis in WEHI-231 B lymphoma cells European Journal of Immunology. 25: 1352-1357. PMID 7539757 DOI: 10.1002/Eji.1830250533 |
0.477 |
|
| 1995 |
Boise LH, Minn AJ, Thompson CB. Receptors that regulate T-cell susceptibility to apoptotic cell death. Annals of the New York Academy of Sciences. 766: 70-80. PMID 7486701 DOI: 10.1111/J.1749-6632.1995.Tb26650.X |
0.446 |
|
| 1995 |
Clarke MF, Apel IJ, Benedict MA, Eipers PG, Sumantran V, González-García M, Doedens M, Fukunaga N, Davidson B, Dick JE, Minn AJ, Boise LH, Thompson CB, Wicha M, Núñez G. A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proceedings of the National Academy of Sciences of the United States of America. 92: 11024-8. PMID 7479929 DOI: 10.1073/Pnas.92.24.11024 |
0.438 |
|
| 1995 |
Minn A, Rudin C, Boise L, Thompson C. Expression of bcl-xL can confer a multidrug resistance phenotype Blood. 86: 1903-1910. DOI: 10.1182/Blood.V86.5.1903.Bloodjournal8651903 |
0.493 |
|
| 1994 |
Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang HG. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proceedings of the National Academy of Sciences of the United States of America. 91: 9238-42. PMID 7937747 DOI: 10.1073/Pnas.91.20.9238 |
0.381 |
|
| 1994 |
Gottschalk AR, Boise LH, Thompson CB, Quintáns J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2 Proceedings of the National Academy of Sciences of the United States of America. 91: 7350-7354. PMID 7518929 DOI: 10.1073/Pnas.91.15.7350 |
0.52 |
|
| 1993 |
Boise LH, Petryniak B, Mao X, June CH, Wang CY, Lindsten T, Bravo R, Kovary K, Leiden JM, Thompson CB. The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and JunB. Molecular and Cellular Biology. 13: 1911-9. PMID 8441422 DOI: 10.1128/Mcb.13.3.1911 |
0.328 |
|
| 1993 |
Boise LH, González-García M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74: 597-608. PMID 8358789 DOI: 10.1016/0092-8674(93)90508-N |
0.502 |
|
| Show low-probability matches. |